FILE:COV/COV-8K-20070615130038.txt.gz
EVENTS:	Results of Operations and Financial Condition	Regulation FD Disclosure	Financial Statements and Exhibits
TEXT:
ITEM: Results of Operations and Financial Condition
ITEM: Regulation FD Disclosure
ITEM: Financial Statements and Exhibits
 
 
 
Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
           
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
           
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
           
Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2 (b))
o
           
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
ITEM 2.02             RESULTS OF OPERATIONS AND FINANCIAL CONDITION
The information disclosed in Item 7.01 of this Current Report on Form 8-K is furnished and incorporated by reference in this Item 2.02.  The unaudited quarterly financial information referred to therein is furnished as Exhibits 99.1, 99.2, 99.3 and 99.4 to this report and incorporated by reference in this Item 2.02.
ITEM 7.01             REGULATION FD DISCLOSURE
The unaudited quarterly financial information furnished with this report and incorporated by reference includes the unaudited quarterly combined statements of income for the Healthcare Businesses of Tyco International Ltd. ("Healthcare Businesses") and the unaudited quarterly segment results for the Healthcare Businesses for each of the four fiscal quarters for the fiscal year ended September 29, 2006 and for each of the first two fiscal quarters for the fiscal year ending September 28, 2007. 
This information should be read in conjunction with the combined financial statements and accompanying notes of the Healthcare Businesses included in the Information Statement of Covidien Ltd. ("Covidien") dated June 8, 2007, which is Exhibit 99.1 to the Current Report on Form 8-K of Covidien filed with the Securities and Exchange Commission on June 8, 2007.  The unaudited quarterly financial information has been prepared on the same basis as the audited combined financial statements and, in the opinion of management, includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the information set forth therein.  This information may not reflect the results of operations that would have resulted had Covidien been operating as an independent, publicly-traded company during such periods.  In addition, it is not necessarily indicative of Covidien's future results of operations.
ITEM 9.01             FINANCIAL STATEMENTS AND EXHIBITS
(d)           Exhibits
 
2
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
3

Exhibit 99.1
 
 Restructuring charges of $21 million relate primarily to severance costs within our Medical Devices segment for the six months ended March 30, 2007. The associated tax benefit was $7 million for the six months ended March 30, 2007 and $1 million and $6 million for the quarters ended and March 30, 2007 and December 29, 2006, respectively. 
(1)
 The Medical Devices segment recorded in-process research and development charges of $8 million in connection with the acquisition of the remaining outstanding shares of Airox S.A. There was no associated tax impact.
(2)

Exhibit 99.2
 
(1)
  The Medical Devices segment recorded in-process research and development charges of $49 million in connection with the acquisition of 100%  of Confluent Surgical, Inc., $11 million in connection with the acquisition of 50% of Airox S.A. and $3 million in connection with the acquisition of over 90% of Floreane Medical Implants, S.A. There was no associated tax impact.
(2)
  Primarily consists of a gain of $45 million associated with the sale of the Radionics product line within the Medical Devices segment. The associated tax provision was $10 million for the fiscal year ended September 29, 2006 and $1 million and $9 million for the quarters ended September 29, 2006, and March 31, 2006, respectively. 

Exhibit 99.3
 

Exhibit 99.4
 
 


